A randomized, placebo-controlled, phase 1 study to evaluate the effects of TAK-063 on ketamine-induced changes in fMRI BOLD signal in healthy subjects.

Rationale: Phosphodiesterase 10A inhibitor TAK-063 has shown effects that suggest efficacy in schizophrenia treatment. Objective: This randomized, double-blind, placebo-controlled, incomplete-crossover study investigated effects of single oral administration of TAK-063 on ketamine-induced changes in...

Descripción completa

Detalles Bibliográficos

Publicado en:	Psychopharmacology Vol. 237; no. 2; pp. 317 - 329
Autores principales:	Yurgelun-Todd, Deborah A., Renshaw, Perry F., Goldsmith, Paul, Uz, Tolga, Macek, Thomas A.
Formato:	Journal Article
Publicado:	Springer Nature Feb2020
Acceso en línea:	Ver este registro en EBSCOhost